Clinical Trial Update: An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase 2/3 trial of trofinetide for Rett syndrome in girls aged 2 to 5 was terminated, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• Trofinetide (trofinetide)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Rett Syndrome | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2024-09-24